Pacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.80, $0.03 worse than the analyst estimate of $0.83. Revenue for the quarter came in at $172 million versus the consensus estimate of $178.59 million.

Today the company is providing full-year 2023 financial guidance as follows:

• EXPAREL net product sales of $570 million to $580 million;
• ZILRETTA net product sales of $115 million to $125 million;
• iovera° net product sales of $17 million to $20 million;
• Non-GAAP Gross margin of 76% to 78%;
• Non-GAAP R&D expense of $70 million to $80 million;
• Non-GAAP SG&A expense of $220 million to $230 million; and
• Stock-based compensation of $51 million to $54 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.